Üçlü negatif meme kanserli hastalarda hastalık nüksü ve sağ kalımı predikte eden faktörlerin incelenmesi
Yükleniyor...
Dosyalar
Tarih
2020
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Trakya Üniversitesi, Tıp Fakültesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Kadınlarda en sık görülen kanser tipi meme kanseridir ve üçlü negatif meme kanseri diğer meme kanseri türlerinden daha kötü seyirlidir. Bu retrospektif çalışmanın amacı üçlü negatif meme kanserli hastalarda hastalık nüksü ve sağ kalımı etkileyen faktörleri saptamayı amaçladık. 1 Ocak 2012 ile 1 Mart 2019 yılları arasında Trakya Üniversitesi İç Hastalıkları Anabilim Dalı Medikal Onkoloji polikliniğine başvurmuş ya da servisinde yatarak tedavi almış, 69 tane üçlü negatif meme kanser tanılı hasta grubunun klinikopatolojik karakteristik nüks ve sağ kalımı predikte eden faktörler ve tedavi yaklaşımı incelenmiştir. Çalışmaya alınan 11 hasta neoadjuvan tedavi, 58 hasta ise adjuvan tedavi grubunu oluşturmaktaydı. Hastaların ortanca hastalıksız sağ kalım süresi 50.2 (24.3-76.0) ay idi. Ortanca genel sağ kalım süreleri ise 123.1 (100.5-145.7) ay idi. Ki 67’si %30’un üzerinde olan hastaların hastalıksız sağ kalımlarının daha kısa olma eğiliminde olduğu gözlendi (HR 4.52 %95 GA 0.96-21.19, p:0.006). Sonuç olarak ileri yaş (>60 yaş) ve neoadjuvan tedavi olan grubun hastalıksız sağ kalım açısından bağımsız bir prediktör olduğu saptandı. Genel sağ kalım ileri yaş hastalarda (>60 yaş) daha düşük olduğu gözlendi. Bu grup hastalar BRCA gen mutasyonu araştırılması için genetik danışmanlık almalıdır. Sağ kalım süreleri ile diğer klinik ve demografik (menarş yaşı, primer tümör yerleşimi, ilk doğum yaşı, doğum öyküsü, postmenapozal dönem, komorbidite varlığı, primer cerrahi, BRCA mutasyonu, histoloji, klinik TNM evre, patolojik evre, grade, lenfovasküler invazyon ya da in situ komponent varlığı ) verileri incelendiğinde anlamlı sonuç saptanmadı. Çalışmamızın retrospektif olması ve hasta sayısının az olması nedeniyle verilerimiz yetersizdi. Yeni tedavi stratejilerini geliştirmek için daha fazla hasta gruplarının olduğu yeni çalışmalara ihtiyaç vardır.
The most common type of cancer in women is breast cancer, and triple negative breast cancer is worse than other types of breast cancer. The aim of this retrospective study was to determine the factors affecting disease recurrence and survival in patients of triple negative breast cancer. Our study included patients who were admitted to medical oncology clinic of Trakya University between January 1, 2012 and March 1, 2019. The clinicopathological characteristic recurrence and survival factors and treatment approach of 69 patients with triple negative breast cancer were investigated. Eleven patients included in the study were neoadjuvant therapy and 58 were adjuvant therapy. The median disease-free survival time of the patients was 50.2 (24.3-76.0) months. Median overall survival was 123.1 (100.5-145.7) months. Disease-free survival tended to be shorter in patients with ki 67 over 30% (HR 4.52 95% CI 0.96-21.19, p: 0.006). As a result, advanced age (> 60 years) and neoadjuvant therapy was found to be an independent predictor for disease-free survival. Overall survival was lower in advanced age patients (> 60 years). This group of patients should receive genetic counseling to investigate BRCA gene mutation. Survival times and other clinical and demographic (menarche age, primary tumor location, age of first birth, birth history, postmenopausal period, presence of comorbidity, primary surgery, BRCA mutation, histology, clinical TNM stage, pathological stage, grade, lymphovascular invasion or In situ component presence), no significant results were found. Our data were insufficient because our study was retrospective and the number of patients was low. New studies with more patient groups are needed to develop new treatment strategies.
The most common type of cancer in women is breast cancer, and triple negative breast cancer is worse than other types of breast cancer. The aim of this retrospective study was to determine the factors affecting disease recurrence and survival in patients of triple negative breast cancer. Our study included patients who were admitted to medical oncology clinic of Trakya University between January 1, 2012 and March 1, 2019. The clinicopathological characteristic recurrence and survival factors and treatment approach of 69 patients with triple negative breast cancer were investigated. Eleven patients included in the study were neoadjuvant therapy and 58 were adjuvant therapy. The median disease-free survival time of the patients was 50.2 (24.3-76.0) months. Median overall survival was 123.1 (100.5-145.7) months. Disease-free survival tended to be shorter in patients with ki 67 over 30% (HR 4.52 95% CI 0.96-21.19, p: 0.006). As a result, advanced age (> 60 years) and neoadjuvant therapy was found to be an independent predictor for disease-free survival. Overall survival was lower in advanced age patients (> 60 years). This group of patients should receive genetic counseling to investigate BRCA gene mutation. Survival times and other clinical and demographic (menarche age, primary tumor location, age of first birth, birth history, postmenopausal period, presence of comorbidity, primary surgery, BRCA mutation, histology, clinical TNM stage, pathological stage, grade, lymphovascular invasion or In situ component presence), no significant results were found. Our data were insufficient because our study was retrospective and the number of patients was low. New studies with more patient groups are needed to develop new treatment strategies.
Açıklama
Anahtar Kelimeler
Üçlü Negatif Meme Kanseri, Genel Sağ Kalım, Hastalıksız Sağ Kalım, Triple Negative Breast Cancer, Overall Survival, Disease-Free Survival
